ResMed (RMD) investor relations material

Fiscal 2026 performance and strategy

• Achieved approximately $5.7B in revenue with 8% constant currency growth and 17% non-GAAP EPS growth.

• Generated $1.65B in free cash flow, investing in business growth and shareholder returns.

• Board and management are aligned on executing the 2030 strategy, aiming to empower 500M people globally.

• Focus areas include sleep health, breathing health, and health tech at home, with digital solutions driving improved outcomes.

• Sustainability initiatives target minimizing environmental footprint and developing durable patient solutions.

Governance and board structure

• Board comprises 10 members, 8 of whom are independent, with annual elections and diverse backgrounds.

• Carol Burt appointed Lead Independent Director, succeeding Ron Taylor after his retirement.

• Four board committees oversee audit, compensation, compliance, and governance, all chaired by independents.

• Board actively oversees strategy, risk management, and participates in director education on key topics.

• PwC selected as new independent auditor, replacing KPMG after 32 years, with a smooth transition.

Human capital and leadership

• Over 11,300 employees worldwide, with a 13% turnover rate and emphasis on diversity and engagement.

• Leadership team combines long-tenured and new executives, supporting growth and strategic execution.

• Compensation programs emphasize pay for performance, aligning management and shareholder interests.

• Executive compensation is competitive with US med tech peers, balancing short- and long-term incentives.